Distribution and elimination of protein therapeutics: A review

Stamford Journal of Pharmaceutical Sciences

Volumn 4, Issue 2, 2011, Pages 1-12

  Sutradhar, Kumar Bishwajit ^a   Khatun, Sabera ^a   Al Mamun, Abdullah ^a   Begum, Mamotaz ^a  

^a STAMFORD UNIVERSITY BANGLADESH   (Bangladesh)

Author keywords

Coagulation factors; Growth hormones; Insulin; Monoclonal antibody; Therapeutic protein

Indexed keywords

BEVACIZUMAB; CETUXIMAB; GALSULFASE; HUMAN GROWTH HORMONE; IMIGLUCERASE; IMMUNOGLOBULIN G; INFLIXIMAB; INSULIN; LEPIRUDIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLASMINOGEN ACTIVATOR; PRAMLINTIDE; PROTEIN; PROTEIN C; RECOMBINANT ANTITHROMBIN III; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT FOLLITROPIN; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; RECOMBINANT LUTEINIZING HORMONE; RITUXIMAB; SALCATONIN; VACCINE;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; KIDNEY CLEARANCE; LIVER; MOLECULAR WEIGHT; PHARMACODYNAMICS; REVIEW;

EID: 84870185095     PISSN: 19997108     EISSN: None     Source Type: Journal    
DOI: 10.3329/sjps.v4i2.10433     Document Type: Review

References (56)

1. Abbokinase Approval Application, FDA (2002). Abbott Laboratories. USA. Available at: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080776.pdf [Accessed on: November, 28, 2011]
2. ActiVery (2011). Protein therapeutics worth $77bn by 2011, says RNCOS. Available at: http://www.activery.com/pharmaceutical-marketnews/168-the-global-protein-therapeutics-market-will-beworth-77bn-by-2011-with-biogenerics-playing-anincreasingly-important-rol. [Accessed on: November 16, 2011].
3. Archived Drug Label of Luveris (2005). Serono, Inc. Available at: http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=5021 [Accessed on: November, 28, 2011]
4. Atkinson AJ (2001). Introduction to clinical pharmacology. In: Atkinson, AJ, Daniels, CE, Dedrick, RL, Grudzinskas, CV, Markey, SP eds. Principles of Clinical Pharmacology. Academic Press. pp. 1-6.
5. Beck A, Wurch T, Bailly C, Corvaia N (2010). Strategies and challenges for the next generation of therapeutic antibodies, Nat. Rev. Immunol. 10: 345-352. http://dx.doi.org/10.1038/nri2747 PMid:20414207
6. Björkman S, Berntorp E (2001). Pharmacokinetics of Coagulation Factors Clinical Relevance for Patients with Haemophilia. Clin Pharmacokinet. 40 (11): 815-832. PMid:11735604
7. Bocci V (1990). Catabolism of therapeutic proteins and peptides with implications for drug delivery. Adv Drug Deliv Rev. 4: 149-69. http://dx.doi.org/10.1016/0169-409X(89)90017-3
8. Braeckman R (2000). Pharmacokinetics and pharmacodynamics of protein therapeutics. In: Reid ER eds. Peptides and protein analysis. New York, Marcel Dekker Inc. pp. 633-69.
9. Cada DJ, Levien TL, Baker DE (2009). Antithrombin (Recombinant). Hospital Pharmacy. 44(9): 785-793. Available at: http://dx.doi.org/10.1310/hpj4409-785
10. Caravella J, Lugovskoy A (2010). Design of nextgeneration protein therapeutics. Current Opinion in Chemical Biology. 14:520-528. http://dx.doi.org/10.1016/j.cbpa.2010.06.175 PMid:20638324
11. Carter PJ (2011). Introduction to current and future protein therapeutics: A protein engineering perspective. Experimental Cell Research. 317: 1261-1269. http://dx.doi.org/10.1016/j.yexcr.2011.02.013 PMid:21371474
12. Cerezyme Product Insert. Genzyme Corporation, USA. Available at: http://www.cerezyme.com/~/media/Files/CerezymeUS/pdf /cerezyme_pi.pdf [Accessed on: November, 28, 2011]
13. Chan AC, Carter PJ (2010). Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 10: 301-316. http://dx.doi.org/10.1038/nri2761 PMid:20414204
14. CHO Consortium. Recombinant protein therapeutic from CHO cells- 20 years and counting. SBE Special Section. Society for Biological Engineering. pp. 40-47.
15. Data Sheet of Avastin. Available at: http://www.medsafe.govt.nz/profs/datasheet/a/Avastininf.pdf [Accessed on: November, 28, 2011]
16. Drugs.com- Online resource on Follistim AQ. Available at: http://www.drugs.com/pro/follistim-aq.html [Accessed on: November, 28, 2011]
17. Drugs.com- Online resource on Fortical. Available at: http://www.drugs.com/pro/fortical.html [Accessed on: November, 28, 2011]
18. Drugs.com- Online resource on Refludan. Available at: http://www.drugs.com/pro/refludan.html [Accessed on: November, 28, 2011]
19. Drugs.com- Online resource on Remicade. Available at: http://www.drugs.com/monograph/remicade.html [Accessed on: November, 28, 2011]
20. Drugs.com- Online resource on Rituximab. Available at: http://www.drugs.com/ppa/rituximab.html [Accessed on: November, 28, 2011]
21. EMEA (2006a). Scientific discussion on Myozyme. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000636/WC500032128.pdf [Accessed on: November, 28, 2011]
22. EMEA (2006b). Scientific discussion on Naglazyme http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000640/WC500024285.pdf [Accessed on: November, 28, 2011]
23. EMEA (2007). Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins. Available at: http://www.tga.gov.au/pdf/euguide/ewp8924904enfin.pdf. [Accessed on: November 16, 2011]
24. Erbitux-Package Inserts. Bristol-Myers Squibb. Available at: http://packageinserts.bms.com/pi/pi_erbitux.pdf [Accessed on: November, 28, 2011]
25. FDA (2007). CEPROTIN [Protein C Concentrate (Human)]. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm119540.pdf [Accessed on: November, 28, 2011]
26. Global Protein Therapeutics Market Analysis (2011). Market research report by RNCOS Industry
27. Research Solutions. Available at: http://www.rncos.com/Report/IM557.htm [Accessed on: November, 28, 2011]
28. GlobalRPh Inc (2011). Available at: http://www.globalrph.com/combination-insulins.htm [Accessed on: November, 28, 2011]
29. Gloff CA, Benet LZ (1990). Pharmacokinetics and protein therapeutics. Advanced Drug Delivery Reviews. 4(3): 359-386. http://dx.doi.org/10.1016/0169-409X(90)90027-P
30. Health Encyclopedia (2011). Thrombate III. Available at: http://healthency.org/Drugs.thrombate-iii.ashx [Accessed on: November, 28, 2011]
31. Kompella A, Lee VHL (1991). Pharmacokinetics of peptide and protein drugs. In: Lee VHL, editor. Peptide and protein drug delivery. New York: Marcel Dekker Inc. pp. 391-484.
32. LaRusso NF. Proteins in bile: how they get there and what they do. Am J Physiol 1984; 247 (3 Pt 1): G199-205. PMid:6383073
33. LeadDiscovery (2005). Therapeutic Proteins. Available at:http://www.leaddiscovery.co.uk/reports/228/Therapeutic_Proteins/ [Accessed on: November 22, 2011]
34. Leader B, Baca QJ, Golan DE (2008). Protein therapeutics: a summary and pharmacological classification. Nature Rev Drug Discov. 7: 21-39. http://dx.doi.org/10.1038/nrd2399 PMid:18097458
35. Maack T (1975). Renal handling of low molecular proteins. Am J Med. 58(1): 57-64. http://dx.doi.org/10.1016/0002-9343(75)90533-1
36. Maack T, Johnson V, Kau ST et al. (1979) Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int. 16: 251-70. PMid:393891
37. Mahmood I (2008). Methods to determine pharmacokinetic profiles of therapeutic proteins. Drug Discovery Today: Technologies. 5(2-3): e65-e69. http://dx.doi.org/10.1016/j.ddtec.2008.12.001
38. Mahmood I, Green MD (2005). Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins. Clin Pharmacokinet. 44 (4): 331-347. http://dx.doi.org/10.2165/00003088-200544040-00001 PMid:15828849
39. Mahmood, I (2006). Pharmacokinetics and pharmacodynamic considerations in the development of therapeutic proteins. In: Mahmood I. eds. Clinical Pharmacology of Therapeutic Proteins. Pine House Publishers, pp. 123-174.
40. Mukherjee S (2011). Protein therapeutics. Available at: faculty.smu.edu/jbuynak/ProteinTherapeuticsMukherjee.pptx [Accessed on: November 16, 2011]
41. Myozyme Product Information. Genzyme Corporation, USA. Available at: http://www.health.gov.au/internet/main/publishing.nsf/Content/lsdp-info/$File/MYOZYME0210.pdf [Accessed on: November, 28, 2011]
42. Neulasta Prescribing Information. Amgen Inc. Available at: http://pi.amgen.com/united_states/neulasta/neulasta_pi_hcp_english.pdf [Accessed on: November, 28, 2011]
43. Neumega Drug Insert. Genetics Institute, Inc. USA. Available at: http://patient.cancerconsultants.com/druginserts/Oprelvekin.pdf [Accessed on: November, 28, 2011]
44. Octagam Product Insert. Octapharma Pharmazeutika Produktionsges.m.b.H, Austria. Available at:http://www.abopharmaceuticals.com/ProductSheets/Octagam_PI.pdf [Accessed on: November, 28, 2011]
45. Powell J, Gurk-Turner C (2002). Darbepoetin alfa (Aranesp). BUMC Proceedings. 15:332-335. PMid:16333460 PMCid:1276633
46. Preusch PC (2001). Equilibrative and concentrative drug transport mechanisms. In: Atkinson AJ, Daniels CE, Dedrick RL, et al., eds. Principles of clinical pharmacology. San Diego (CA): Academic Press. pp. 201-22.
47. Procrit Label. Amgen Manufacturing, Limited. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103234s5199lbl.pdf [Accessed on: November, 28, 2011]
48. PROLOR Biotech Inc. (2006). The Therapeutic Proteins Industry. Available at: http://www.prolorbiotech.com/?CategoryID=201 [Accessed on: November 22, 2011]
49. Reichert JM (2003). Trends in development and approval times for new therapeutics in the United States. Nature Rev Drug Discov. 2: 695-702. http://dx.doi.org/10.1038/nrd1178 PMid:12951576
50. Reichert JM (2008). Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol. 9: 423-430. http://dx.doi.org/10.2174/138920108786786358 PMid:19075682
51. Schwartz RS, Abildgaard CF, Aledort LM et al. (1990). Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N Engl J Med. 323: 1800-5. http://dx.doi.org/10.1056/NEJM199012273232604 PMid:2123300
52. Serostim Product Monograph (2007). EMD Serono Canada Inc. Available at: http://www.emdserono.ca/cmg.emdserono_ca/en/images/Serostim_Prescribing_Information_tcm463_17911.pdf?Version= [Accessed on: November, 28, 2011]
53. Supersaxo A, Hein W, Gallati H et al. (1988). Recombinant human interferon alpha-2a: delivery to lymphoid tissue by selected modes of application. Pharm Res. 8: 472-6. http://dx.doi.org/10.1023/A:1015957022073 PMid:3244653
54. Supersaxo A, Hein WR, Steffen H (1990). Effect of molecular weight on the lymphatic absorption of watersoluble compounds following subcutaneous administration. Pharm Res. 2: 167-9. http://dx.doi.org/10.1023/A:1015880819328 PMid:2137911
55. Symlin Product Literature (2008). Amylin Pharmaceuticals, Inc. Available at: http://documents.symlin.com/SYMLIN_PI.pdf [Accessed on: November, 28, 2011]
56. Wright CM, Wright RC, Eshleman JR, Ostermeiera M (2011). Protein therapeutic modality founded on molecular regulation. PNAS Early Edition. www.pnas.org/cgi/doi/10.1073/pnas.1102803108.